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Abstract. 
 
To investigate possible involvement of the 
mitogen-activated protein (MAP) kinases ERK1 and 
ERK2 (extracellular signal-regulated kinases) in so-
matic cell mitosis, we have used indirect immunofluo-
rescence with a highly specific phospho-MAP kinase 
antibody and found that a portion of the active MAP 
kinase is localized at kinetochores, asters, and the mid-
body during mitosis. Although the aster labeling was 
constant from the time of nuclear envelope breakdown, 
the kinetochore labeling first appeared at early 
prometaphase, started to fade during chromosome con-
gression, and then disappeared at midanaphase. At
telophase, active MAP kinase localized at the midbody. 
Based on colocalization and the presence of a MAP ki-
nase consensus phosphorylation site, we identified the 
kinetochore motor protein CENP-E as a candidate mi-
totic substrate for MAP kinase. CENP-E was phos-
phorylated in vitro by MAP kinase on sites that are 
known to regulate its interactions with microtubules 
and was found to associate in vivo preferentially with 
the active MAP kinase during mitosis. Therefore, the 
presence of active MAP kinase at specific mitotic struc-
tures and its interaction with CENP-E suggest that 
MAP kinase could play a role in mitosis at least in part 
by altering the ability of CENP-E to mediate interac-
tions between chromosomes and microtubules. 
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ACTIVATED
 
 protein kinases (MAP ki-
nases)
 
1
 
 or extracellular signal–regulated kinases
(ERKs) are serine/threonine-specific protein ki-
nases (Ray and Sturgill, 1987; Rossomando et al., 1989;
Boulton et al., 1991) that are activated in response to ex-
tracellular signals and play important roles as effectors for
diverse cellular functions, including growth, differentia-
tion, movement, and secretion (L’Allemain, 1994). MAP
kinases are activated by dual threonine and tyrosine phos-
phorylation on a TEY sequence located in the regulatory
lip and these phosphorylations are both necessary and suf-
ficient for enzymatic activation (Anderson et al., 1990;
Zhang et al., 1995). Both phosphorylations are catalyzed
by MEKs (MAPK/ERK Kinases), which are dual-specific-
ity MAP kinase kinases (Crews et al., 1992; Nakielny et al.,
1992; Her et al., 1993; Zheng and Guan, 1993). MEKs, in
turn, are activated by phosphorylation on serine residues
by various serine/threonine protein kinases, especially
members of the Raf family (Dent et al., 1992; Huang et al.,
1993; Alessi et al., 1994; Zheng and Guan, 1994).
The best-studied function of MAP kinases has been in
 
the regulation of the G
 
o 
 
®
 
G
 
1 
 
®
 
S transition (Kahan et al.,
1992; Meloche et al., 1992; Pages et al., 1993). After activa-
tion in response to extracellular agonists, MAP kinases
translocate to sites of action, including the nucleus (Chen
et al., 1992; Gonzalez et al., 1993; Lenormand et al., 1993).
Phosphorylation of transcription factors and concomitant
regulation of gene expression by MAP kinases is a key
early event in initiating cell cycle progression by growth
factors. The localization of activated MAP kinase at its nu-
clear site of action is believed to be essential for these
events.
Another well-established role of MAP kinase is in the
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regulation of meiosis in 
 
Xenopus
 
, where it functions as an
effector for Mos, a germline-specific serine/threonine ki-
nase. Mos initiates oocyte maturation in meiosis I by acti-
vating the maturation-promoting factor (MPF) and func-
tions in metaphase II as a component of the cytostatic
factor (CSF) in unfertilized eggs. Mos is also essential for
CSF function in mouse oocytes (Vande Woude, 1994).
Mos can activate MEK in vitro
 
 
 
(Nebreda et al., 1993;
Posada et al., 1993) and is therefore considered, like Raf,
to be able to function as a MAP kinase kinase kinase. In
 
Xenopus
 
, oocyte maturation in the presence of Mos was
inhibited when MAP kinase activation was prevented by
injection of anti-MEK neutralizing antibodies (Kosako et
al., 1994
 
b
 
) or MKP-1, a MAP kinase phosphatase (Gotoh
et al., 1995). Conversely, the injection of active thiophos-
phorylated MAP kinase (Haccard et al., 1995) or mRNA
of constitutively activated MEK (Gotoh et al., 1995) mim-
icked the effects of Mos with respect to oocyte maturation.
In the case of 
 
Xenopus
 
 early embryos, microinjection of
thiophosphorylated MAP kinase induced a metaphase ar-
rest resembling the CSF arrest induced by Mos (Haccard
et al., 1993), whereas injection of anti-MEK neutralizing
antibody prevented the Mos-induced arrest (Kosako et al.,
1994
 
a
 
). Thus, it is clear that MPF activation by Mos and
the CSF activity of Mos are mediated by MAP kinase.
Substantial evidence indicates that MAP kinase also
plays a role in the spindle checkpoint in 
 
Xenopus
 
 egg ex-
tracts. This checkpoint is activated by chromosome mis-
alignment or a defective spindle and prevents entrance
into anaphase. 
 
Xenopus
 
 egg extracts supplemented with
sperm nuclei and treated with nocodazole were found to
arrest in a mitotic state with high cyclin-dependent kinase
2 (cdc2)/cyclin B and MAP kinase activity (Minshull et al.,
1994). Addition of the MAP kinase phosphatase MKP-1
into the M phase–arrested extracts resulted in MAP ki-
nase inactivation, cyclin B destruction, and exit from the
arrest. If MKP-1 phosphatase addition preceded nocoda-
zole treatment, the extracts cycled without arrest. Simi-
larly, the arrest did not occur in egg extracts from which
MAP kinase had been immunodepleted (Takenaka et al.,
1997). Therefore, active MAP kinase is required for both
the establishment and maintenance of the M phase arrest
induced by spindle depolymerization in these egg extracts.
Likewise, maintenance of elevated MAP kinase activity
after fertilization blocks cell cycle progression at several
points in the first postfertilization cell cycle, including re-
pression of DNA synthesis (Tachibana et al., 1997), pre-
vention of the G
 
2
 
 to M phase transition, or blockage of M
phase progression (Abrieu et al., 1997; Walter et al., 1997;
Bitangcol et al., 1998).
Although MAP kinase has established roles in germline
meiosis and in the spindle checkpoint in frog egg extracts,
its functions in somatic cell mitosis are less clear. When in-
jected into mitotic cultured PtK1 cells, Mos became associ-
ated with kinetochores, induced an abnormal spindle mor-
phology, and blocked the formation of the metaphase
plate (Wang et al., 1994). Similarly, other candidate activa-
tors of the MAP kinase cascade, such as Ras and Src, have
been reported to induce genomic instability and abnormal
mitosis (Hagag et al., 1990; Denko et al., 1994) or are re-
quired for M phase entrance (Roche et al., 1995), respec-
tively. However, it is not known whether these effects are
 
mediated by MAP kinase. The most direct approach to ex-
amine the relation between MAP kinase and somatic cell
division was the report of Wang et al., 1997. These workers
showed that XTC cells microinjected with the MAP kinase
phosphatase XCL100 did not display the characteristic mi-
totic block when treated with nocodazole. This is consis-
tent with the hypothesis that sustained MAP kinase activ-
ity might be required for the spindle checkpoint in somatic
cells, as it is in cycling egg extracts. However, recent work
suggests that these functions could be ascribed to the p38
stress-activated protein kinase, which is a MAP kinase ho-
mologue (Takenaka et al., 1998).
Here we present evidence that supports the involvement
of MAP kinase in normal somatic cell mitosis. Active
MAP kinase was localized at kinetochores, asters, and the
midbody of dividing PtK1 cells, using a phospho-MAP ki-
nase antibody that is specific for the dually phosphory-
lated and activated MAP kinases (ERK1 and ERK2). The
activated MAP kinase appeared on kinetochores during
early prometaphase and became undetectable by midana-
phase. Thus, the active MAP kinase was located at a site
where it could play a role in regulation of mitotic progres-
sion, and the time course of its appearance and disappear-
ance was consistent with a role in the regulation of chro-
mosome movement. We also show that MAP kinase is
able to phosphorylate the kinetochore motor protein
CENP-E on sites that regulate the interaction of cen-
tromere-binding protein E (CENP-E) with microtubules.
Finally, we demonstrate that MAP kinase and CENP-E
can be coimmunoprecipitated, with CENP-E interacting
preferentially with inactive MAP kinase during interphase
and with phosphorylated MAP kinase during mitosis.
Taken together, the results raise the possibility that MAP
kinase could play a role in mitotic progression, at least in
part, by altering the ability of CENP-E to mediate the in-
teractions between chromosomes and microtubules.
 
Materials and Methods
 
Cell Culture
 
PtK1, NIH3T3, HeLa, and HeLa S3 cells were obtained from the Ameri-
can Type Culture Collection (Rockville, MD). PtK1 and HeLa S3 cells
were grown as previously described (Renzi et al., 1997). In some experi-
ments, the mitotic yield of PtK1 cells was increased by a 3–5-h treatment
with 5 
 
m
 
g/ml of vinblastine (Sigma Chemical Co., St. Louis, MO). NIH3T3
cells and CCL39 hamster fibroblast were maintained at 37
 
8
 
C and 7.5%
CO
 
2
 
 in DME containing 10% FCS. HeLa cells were grown at 37
 
8
 
C and
5% CO
 
2
 
 in Iscove’s media containing 10% FCS.
To induce quiescence, NIH3T3 and CCL39 cells were grown in 10%
FCS DME to 50% confluency, after which they were starved in DME con-
taining 0.2% FCS for 25 h. For stimulation, 20% FCS was added for 15 or
5 min, respectively. PtK1 cells were grown to 80% confluency in 10% FCS
MEM and then, without serum deprivation, were stimulated for 15 min
with EGF (0.2 
 
m
 
g/ml).
For the CENP-E and MAP kinase coimmunoprecipitation experi-
ments, HeLa cells were grown to 60% confluency. The cells were arrested
at mitosis by a 15–17-h treatment with 0.03 
 
m
 
g/ml of nocodazole (Sigma
Chemical Co.).
 
Antibodies
 
The rabbit phospho-MAP kinase antibody was raised against the phos-
phopeptide CHTGFLpTEpYVATR. The peptide was coupled to keyhole
limpet hemocyanin (KLH) and injected into rabbits to raise polyclonal an-
tisera (Quality Controlled Biochemicals, Inc., Hopkinton, MA). The poly- 
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clonal antibodies were negatively selected by repeated passage over a col-
umn of nonphosphorylated CHTGFLTEYVATR peptide coupled to
KLH, and then positively selected by passage over a column of the phos-
phopeptide coupled to BSA. A concentration of 8.5 
 
m
 
g/ml was used for
immunofluorescence and 1.7 
 
m
 
g/ml for Western blotting.
For ERK2-specific recognition by Western blotting, the monoclonal
ERK2 antibody 05-157 (Upstate Biotechnology Inc., Lake Placid, NY)
was used at a concentration of 0.1 
 
m
 
g/ml, at which it recognizes phosphor-
ylated and unphosphorylated p42 ERK2. For hemagglutinin (HA)-tagged
ERK2 immunoprecipitations, 18 
 
m
 
g of monoclonal anti-HA antibody
12CA5 (Berkeley Antibody Co., Richmond, CA) was used per immuno-
precipitation. The human CENP-E protein was immunoprecipitated with
the affinity-purified rabbit antibody 6A (9 
 
m
 
g/ml) that was generated
against the central portion of CENP-E (amino acids 1,250–1,558), whereas
Western blotting was performed with the same antibody at a concentra-
tion of 0.54 
 
m
 
g/ml. MAP kinase immunoprecipitations from HeLa cells
were done with the polyclonal rabbit antibody TR10, made against recom-
binant ERK2 conjugated to KLH.
All the secondary fluorophore-conjugated antibodies used in indirect
immunofluorescence were obtained from Jackson ImmunoResearch Lab-
oratories (West Grove, PA). The Texas red–conjugated goat anti–rabbit
antibody and the fluorescein (FITC)-conjugated goat anti–human anti-
body were used at a concentration of 7.5 
 
m
 
g/ml. The human autoimmune
CREST (calcinosis/Raynaud’s phenomenon/esophageal dysmotility/scle-
rodactyly/telangiectasia variant of scleroderma) scleroderma serum was a
gift of J.B. Rattner (University of Calgary, Alberta, Canada).
 
Preparation of Cell Lysates
 
For whole cell lysis experiments, PtK1 and NIH3T3 cells were grown to
80% confluency and then lysed in Laemmli sample buffer. The cell lysate
was then sonicated, clarified by centrifugation, protein concentration de-
termined, and then 100 
 
m
 
g of protein was used for SDS-PAGE.
CCL39 fibroblasts, stably transfected with HA-tagged wild type ERK2
or ERK2 phosphorylation site mutants (Her et al., 1993), were washed
twice in ice-cold PBS and then lysed in cold lysis buffer (50 mM Hepes,
pH 7.5, 100 mM NaCl, 2 mM EDTA, 1% NP-40, 1 
 
m
 
M pepstatin, 1 
 
m
 
g/ml
leupeptin, 1 mM PMSF, 0.2 mM Na vanadate, 2 
 
m
 
g/ml aprotinin, 40 mM
4-nitrophenyl phosphate-disodium salt [PNPP], 50 mM 
 
b
 
-glycero-phos-
phate, 2 mM DTT). Samples were centrifuged at 14,000 rpm for 15 min in
a microfuge and protein concentration was estimated by Coomassie dye
labeling (Bio-Rad Laboratories, Hercules, CA) before immunoprecipita-
tion.
For CENP-E immunoprecipitations, cells were washed twice in ice-cold
PBS and lysed in cold hypotonic buffer (20 mM Hepes, pH 7.4, 2 mM
EGTA, 2 mM MgCl
 
2
 
 plus above mentioned inhibitors; used in Fukuda et
al., 1997) and centrifuged for 20 min at 14,000 rpm.
 
Immunoprecipitation
 
Monoclonal anti-HA antibody 12CA5, affinity-purified rabbit anti-
CENP-E 6A antibody or rabbit TR10 antibody were preabsorbed for 1 h
at 4
 
8
 
C to protein A–agarose (Boehringer Mannheim Corp., Indianapolis,
IN) before incubation with 500 
 
m
 
g of CCL39 cell extract for 4 h, 300 or 800
 
m
 
g of HeLa cell extract for 3 h at 4
 
8
 
C, respectively. CENP-E immunopre-
cipitates were transferred to Wizard minicolumns and washed on a vac-
uum manifold (Promega Corp., Madison, WI). Immunoprecipitates were
washed four times with lysis buffer before Laemmli sample buffer was
added. The samples were resolved by SDS-PAGE and transferred to ni-
trocellulose for blotting.
 
Immunoblotting
 
All blotting was performed using nitrocellulose (Protran; Schleicher &
Schuell, Dassel, Germany). The blocking and primary antibody steps were
done at 37
 
8
 
C for 1 h in 5% dry milk in PBS/0.1% Tween 20. The second-
ary HRP-conjugated anti-mouse and anti-rabbit antibodies or protein
A–HRP were incubated for 1 h at room temperature in PBS/0.1% Tween
20. Subsequently, enhanced chemiluminescence was performed using the
Amersham Life Science kit (Arlington Heights, IL). Membranes were
stripped with stripping buffer (62.5 mM Tris, pH 6.8, 2% SDS, 1% 
 
b
 
-mer-
captoethanol) for 10 min at 65
 
8
 
C before reprobing.
 
Cell Fixation and Immunofluorescence
 
NIH3T3 and PtK1 cells (see Fig. 1, 
 
C 
 
and 
 
D
 
) were stimulated with FCS or
 
EGF, rinsed once with PBS, and then fixed in 0.2% acrolein (Polyscience,
Inc., Warrington, PA), 4% formaldehyde, 0.2% Triton X-100, and 2 mM
Na vanadate in PBS for 20 min at room temperature. Cells were then
quenched with 0.025% NaBH
 
4
 
, 2% glycine in PBS twice for 5 min, and
then once for 10 min. Cells were then washed twice with PBS/0.05%
Tween 20.
PtK1 cells in Figs. 3, 4, and 5 were first rinsed with PHEM (60 mM
Pipes, 25 mM Hepes, pH 6.9, 10 mM EGTA, 4 mM MgSO
 
4
 
) and extracted
for 5 min at room temperature with PHEM plus 1% CHAPS and 1 
 
m
 
M
pepstatin, 1 
 
m
 
g/ml leupeptin, 2 
 
m
 
g/ml aprotinin, 50 mM 
 
b
 
-glycero-phos-
phate and 0.2 mM Na vanadate. Cells were then fixed in 1% formalde-
hyde in PHEM for 15 min. Cells were rinsed twice with MBST (10 mM
MOPS, 150 mM NaCl, 0.05% Tween 20, pH 7.4).
Cells for immunofluorescence were blocked with 20% boiled normal
goat serum (NGS; Sigma Chemical Co.) in MBST whereas the primary
and secondary antibodies were diluted in MBST containing 5% boiled
NGS. Cells were washed with PBS/0.05% Tween 20 for acrolein-fixed
cells and MBST for extracted and formaldehyde-fixed cells. All incuba-
tions were done by rocking at room temperature for 1 h. After the last
wash, cells were counterstained with the DNA dye 4
 
9
 
,6-diamidino-2-phe-
nylindole (DAPI; Sigma Chemical Co.) at 0.5 
 
m
 
g/ml and were mounted on
slides with Vectashield mounting media (Vector Laboratories, Burlin-
game, CA) containing 10 mM MgSO
 
4
 
. Slides were viewed with a Leitz
DMRBE microscope and pictures were taken under the same conditions
with the Leitz Vario Orthomat camera (Leica Ltd., Wetzlar, Germany).
Subsequently, scanned images were processed using Adobe Photoshop
and Illustrator software (Adobe Systems, San Jose, CA).
For the peptide-blocking experiments, the peptides (in an excess of 10-
fold mol/mol over antibodies) were preincubated with phospho-MAP ki-
nase antibody and CREST serum for 1 h at room temperature in PBS. Af-
ter the incubation, the antibodies were applied to extracted and fixed cells
that were previously blocked in 20% NGS in MBST.
 
Chromosome Isolation and Immunofluorescence
 
Chromosomes were prepared from a 500-ml HeLa S3 culture containing
 
z
 
5 
 
3 
 
105 cells/ml as previously described (Renzi et al., 1997), except that
the glycerol gradient step was omitted and the final chromosome pellet
was resuspended in 30 ml of the extraction/lysis buffer.
The isolated chromosomes were pelleted onto precoated (1 mg/ml
poly-
 
l
 
-lysine in water for 30 min) 18-mm-round coverslips (Fisher Scien-
tific Co., Pittsburgh, PA) by centrifugation at 1,200 
 
g
 
 for 5 min and then
fixed with 1% formaldehyde in PHEM. Immunofluorescence was then
performed as described above.
 
In Vitro Phosphorylation Assay
 
p42 ERK2 was expressed as a soluble nonfusion protein in 
 
Escherichia
coli 
 
and purified as described (Wu et al., 1991). It was then in vitro phos-
phorylated and activated by constitutively active recombinant MEK1 en-
zyme. The specific activity of MAP kinase was estimated to be 1.2 
 
m
 
mol/
min per milligram, using myelin basic protein as a substrate. The COOH-
terminal portion (amino acids 2,295–2,663) of human CENP-E proteins
(wild-type and mutant) were made from bacteria as a glutathione-S-trans-
ferase (GST) fusion proteins. The CENP-E purification and removal of
GST was done as previously described (Liao et al., 1994). The CENP-E
mutant (CENP-E4A), created by site-directed mutagenesis, has alanines
in the place of serines 2,567, 2,570, 2,601, and 2,616. The in vitro phos-
phorylation of 1.5 
 
m
 
g of the COOH-terminal CENP-E protein (
 
z
 
45 kD)
by 160 ng of active MAP kinase was performed at 30
 
8
 
C for 15 min in a fi-
nal volume of 40 
 
m
 
l containing 25 mM Hepes, pH 7.5, 10 mM Mg
(CH
 
3
 
COO)
 
2
 
, 1 mM dithiothreitol, and 0.02 mM [
 
g
 
-
 
32
 
P]ATP (
 
z
 
22,500 cpm/
pmol). Reactions were terminated with sample buffer, products resolved
by SDS-PAGE, transferred to nitrocellulose, and then exposed to film. 
 
Results
 
Phospho-MAP Kinase Antibody Specifically Recognizes 
the Dually Phosphorylated Form of the ERKs
 
To determine the cellular localization of activated MAP
kinase during mitosis, it was necessary to generate an anti-
body that was highly specific for the dually phosphory-
lated, active form of the enzyme and that could be used in 
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immunocytochemistry as a surrogate for enzyme assays.
The phosphopeptide CHTGFLpTEpYVATR correspond-
ing to the region in MAP kinase containing the activating
phosphothreonine and phosphotyrosine residues was used
as an antigen for antibody production in rabbits and for
the subsequent antibody affinity purification, as described
in Methods. This sequence is identical in both ERK1 and
ERK2 and is conserved in vertebrates.
The specificity of the phospho-MAP kinase antibody
was first determined by Western blotting whole cell lysates
of NIH3T3 fibroblasts and of PtK1 rat kangaroo epithelial
cells, which were used in the immunofluorescence studies
described below. When cells were stimulated with FCS
(Fig. 1 
 
A
 
) or EGF (Fig. 1 
 
B
 
), the only proteins that reacted
with the phospho-MAP kinase antibody corresponded to
the phosphorylated forms of the MAP kinases p44 ERK1
and p42 ERK2. However, in serum-deprived cells, only
low basal levels of phospho-ERK1 and phospho-ERK2
could be detected using the phospho-MAP kinase anti-
body.
Reprobing the same blot with a monoclonal antibody
against ERK2 demonstrated that the upper band here cor-
responded to the phosphorylated, activated, and mobility-
shifted ERK2 that comigrated with the ERK2 band de-
tected with the phospho-MAP kinase antibody. The
ERK2 blot also showed that substantial amounts of the
protein remained unphosphorylated and was not recog-
nized by the phospho-MAP kinase antibody.
The phospho-MAP kinase antibody was also used to an-
alyze MAP kinase activation by indirect immunofluores-
cence. NIH3T3 cells (Fig. 1 
 
C
 
) or PtK1 cells (Fig. 1 
 
D
 
)
were stimulated with either serum or EGF, respectively.
The cells were fixed with acrolein/formaldehyde and
stained with the phospho-MAP kinase antibody that was
then visualized with a secondary antibody conjugated to
Texas red. The intensity of the immunofluorescent signal
increased substantially after stimulation in both cases, and
the activated MAP kinase was observed to concentrate in
the nucleus, as previously reported (Chen et al., 1992;
Gonzalez et al., 1993; Lenormand et al., 1993). The degree
of nuclear concentration of the activated MAP kinase was
more evident in the NIH3T3 than in the PtK1 cells.
The specificity of the phospho-antibody for the individ-
ual MAP kinase phosphoresidues was determined using a
panel of cell lines expressing various phosphorylation site
mutants of ERK2 tagged with the HA epitope: wild-type
Figure 1. Specificity of phos-
pho-MAP kinase antibody.
(A) Phospho-MAP kinase
immunoblot of whole cell
lysate from NIH3T3 fibro-
blasts maintained in 10% FCS
containing media (asynch.);
serum deprived (0.2% FCS)
for 25 h (2 FCS) or serum
deprived and then stimulated
for 15 min with 20% FCS
(1 FCS). Right, correspond-
ing ERK2 monoclonal blot,
showing the total amount of
phosphorylated and unphos-
phorylated ERK2. (B) Phos-
pho-MAP kinase immuno-
blot of whole cell lysate from
PtK1 epithelial cells main-
tained in media with 10%
FCS (2 EGF) or EGF sti-
mulated (0.2 mg/ml; 15 min)
(1 EGF). Next to it is the cor-
responding monoclonal ERK2
antibody blot. (C) Indirect
immunofluorescence of acro-
lein/formaldehyde fixed and
phospho-MAP kinase anti-
body labeled NIH3T3 cells
that were either serum de-
prived (0.2% FCS) for 25 h
(2  FCS) or serum stimu-
lated (20% FCS) for 15 min
(1  FCS). (D) The corre-
sponding immunofluores-
cence of PtK1 cells either
maintained in 10% FCS me-
dia (2 EGF) or stimulated
with EGF (0.2 mg/ml; 15 min)
(1 EGF). Bar, 10 mm. 
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(wt), T183A (TA), Y185F (YF), and the double mutant
T183A/Y185F (TAYF) (Her et al., 1993). The cells were
serum deprived and left untreated or serum stimulated
and the tagged ERKs were immunoprecipitated with a
HA-specific antibody. The immunoprecipitated proteins
were resolved on SDS gels and their recognition by phos-
pho-MAP kinase antibody was then assessed by Western
blotting (Fig. 2 
 
A
 
). The antibody reacted strongly only
with the wild-type enzyme from serum-stimulated cells.
Weaker reactivity was also seen in the YF mutant, but
only when the amount of MAP kinase loaded was in great
excess compared with the other mutants (Fig. 2 
 
B
 
). As
shown previously (Her et al., 1993), phosphorylation at ei-
ther T183 or Y185 is sufficient to cause MAP kinase to dis-
play an electrophoretic mobility shift, and the double
TAYF mutant did not shift at all. These data demonstrate
that our phospho-MAP kinase antibody does not react de-
tectably with unphosphorylated or tyrosine-phosphory-
lated MAP kinase, weakly with the threonine phosphory-
lated enzyme and strongly with the dually phosphorylated
and activated MAP kinase. Reactivity with this antibody
thus is indicative of an activated enzyme, and can be used
as a surrogate for enzyme assays.
 
Phospho-MAP Kinase Localizes at
Kinetochores, Asters, and Midbody during Somatic
Cell Mitosis
 
The localization of active MAP kinase during mitosis was
determined by indirect immunofluorescence analysis of
PtK1 cells. These cells were selected for study because of
their large size, small chromosome number, and flat mor-
phology during mitosis. Initially, we used cells treated with
vinblastine to increase the mitotic yield. When mitotic
cells were fixed with formaldehyde or acrolein/formalde-
hyde and then probed with anti–phospho-MAP kinase and
Texas red-conjugated secondary antibody, the fluorescent
signal was broadly distributed throughout the cell (data
not shown). However, there were concentrations of in-
creased intensity of staining, suggesting that activated
MAP kinase might be concentrated (although not exclu-
sively located) at specific subcellular structures.
Figure 2. Specificity of phospho-MAP kinase an-
tibody for the dually phosphorylated form of
ERKs. (A) Phospho-MAP kinase immunoblot of
hemagglutinin (HA) immunoprecipitated wild-
type HA-ERK2 (wt) and HA-ERK2 phosphory-
lation site mutants (T183A [TA]; Y185F [YF];
T183A/Y185F [TAYF]) from stable expressing
CCL39 fibroblasts. The cells were grown in 10%
FCS containing media and then were either se-
rum deprived (0.2% FCS) for 25 hours (2 FCS)
or serum deprived and then stimulated (20% FCS) for 5 min (1 FCS). (B) The corresponding ERK2 monoclonal immunoblot of the
same membrane. Proteins were visualized by enhanced chemiluminescence.
Figure 3. Phospho-MAP
kinase localization at ki-
netochores of a vinblastine-
treated cell. Indirect immu-
nofluorescence was applied
on this vinblastine treated,
extracted, and fixed PtK1
cell. It was double labeled
with phospho-MAP kinase
antibody (red) and CREST
autoimmune serum (green).
(A) Phase contrast; (B) phos-
pho-MAP kinase antibody;
(C) CREST serum; (D) dou-
ble labeling picture. In the
latter, the kinetochores are
seen in yellow, indicating
colocalization of CREST and
phospho-MAP kinase signal.
The paired dot signal of the
kinetochores is due to ki-
netochore labeling of sister
chromatids. Note that no
phospho-MAP kinase aster
labeling is observed when the
mitotic spindle is disrupted.
Bar, 10 mm.The Journal of Cell Biology, Volume 142, 1998 1552
To reveal the subcellular locations where activated
MAP kinase was concentrated, vinblastine-treated PtK1
cells arrested in mitosis were first extracted with CHAPS
detergent, then formaldehyde fixed and labeled with phos-
pho-MAP kinase antibody. The phospho-MAP kinase sig-
nal appeared as paired dots that resembled kinetochore
labeling of sister chromatids (Fig. 3 B). To determine
whether these paired dots were in fact kinetochores, the
cells were also labeled with CREST autoimmune serum,
which reacts with kinetochore proteins (Earnshaw and
Rothfield, 1985). The CREST signal was visualized with
FITC-conjugated secondary antibody, which displayed
paired dots apparently identical to those seen with the
phospho-MAP kinase antibody (Fig. 3 C). Double labeling
with the two fluorophores yielded yellow paired dots, indi-
cating colocalization of the phospho-MAP kinase and
CREST signals (Fig. 3 D). Thus, activated MAP kinase is
localized to kinetochores during prometaphase in vinblas-
tine-treated cells.
To determine whether the kinetochore localization of
Figure 4. Localization of phospho-MAP kinase
during different stages of mitosis. Indirect immu-
nofluorescence was performed on 1% Chaps ex-
tracted and 1% formaldehyde fixed PtK1 epithe-
lial cells. The cells were labeled with the
phospho-MAP kinase antibody (red) and coun-
terstained with the DNA dye, DAPI (blue). In
one case (interphase stage), the phase-contrast
picture is shown instead of DAPI. Arrow, kinet-
ochores in early prometaphase, asters in late
prometaphase, and midbody in telophase. Bar,
10 mm.Zecevic et al. Active MAP Kinase in Mitosis 1553
MAP kinase was artificially induced by the microtubule-
disrupting agent, we examined the location of phospho-
MAP kinase in cells at various stages of mitosis in asyn-
chronous cultures (Fig. 4). In interphase, phospho-MAP
kinase had a punctate nuclear staining and was excluded
from the nucleolus. In prophase, phospho-MAP kinase la-
beling was similar to the interphase stage, but the punctate
character was less sharply defined. In prometaphase the
pattern of phospho-MAP kinase labeling changed drasti-
cally: the punctate pattern disappeared and the labeling
was present only as doublets corresponding to kineto-
chores of sister chromatids and in asters. (Note that aster
labeling was not observed in the vinblastine-treated cell
shown in Fig. 3 in which the microtubules were depoly-
merized). The kinetochore labeling appeared to be stron-
ger in early than in late prometaphase, suggesting a de-
crease in phospho-MAP kinase signal as chromosomes
congress toward the equatorial plate. At metaphase the
phospho-MAP kinase staining at asters was maintained,
whereas the kinetochore staining was slightly diminished.
Aster staining persisted while kinetochore staining contin-
ued to drop as cells progressed into anaphase with kineto-
chore staining being virtually absent by midanaphase.
During telophase and cytokinesis aster labeling was main-
tained and was accompanied by substantial staining of the
contractile ring or midbody. Finally, after cytokinesis the
reformed nuclei displayed the characteristic punctate in-
terphase staining seen in exponential cultures (data not
shown). Thus, it is clear that the appearance of activated
MAP kinase at various subcellular sites during mitosis is
regulated either by localization or by a phosphorylation
and dephosphorylation cycle.
Whereas active MAP kinase signal at the kinetochores
was absent in interphase and prophase, the CREST label-
ing was localized at kinetochores in both instances (data
not shown). We cannot distinguish between the possibility
that the active enzyme is not at the kinetochores during
those cycle stages or that the phosphoepitope is somehow
masked and therefore not recognized by the antibody.
Active MAP kinase was detected at kinetochores only
when tyrosine and serine/threonine phosphatase inhibitors
(vanadate and b glycerol-phosphate respectively) were in-
cluded in the extraction solution. When the inhibitors
were omitted, the kinetochore labeling was undetectable
(data not shown). This suggests that the antibody reactiv-
ity depends on a phosphoepitope.
The kinetochore phospho-MAP kinase labeling was also
detected with other fixation methods (acrolein/formalde-
hyde), as well as with antibody against total ERK2. In the
former case, the background labeling was very high, which
obscured the visualization of the kinetochore labeling. In
the latter case, the kinetochore labeling was evident only if
cells were previously treated with vinblastine, a procedure
that maximized the phospho-MAP kinase signal.
Specificity of Phospho-MAP Kinase Labeling
at Kinetochores
Although the phospho-specific antibody was highly spe-
cific on Western blots, it was important to verify its speci-
ficity in immunocytochemical procedures. To test this, we
determined that the signal could be blocked with the anti-
genic phosphopeptide (CHTGFLpTEpYVATR) but not
the cognate unphosphorylated peptide (Fig. 5, B and E).
Note that the phosphopeptide, while blocking reactivity of
the cells with phospho-MAP kinase antibody, had no ef-
fect on reactivity with CREST antibody (Fig. 5, C and F).
Comparable blocking of immunoreactivity was obtained
when phosphorylated and activated recombinant MAP
kinase was used as the blocking agent. Similarly, non-
phosphorylated, inactive MAP kinase did not block immu-
noreactivity (data not shown). No immunoreactivity was
detected with preimmune serum or with primary or sec-
ondary antibodies alone (data not shown). Additionally,
microinjection of the phospho-MAP kinase antibody into
mitotic cells localized the antibody on kinetochores and
asters (data not shown). Thus, this antibody is as specific
for phosphorylated and activated MAP kinase in immuno-
cytochemical assays as it is in Western blots.
Phospho-MAP Kinase Localizes at Kinetochores of 
Isolated Chromosomes
To confirm the kinetochore localization of phospho-MAP
kinase, we examined its localization on isolated chromo-
somes prepared from mitotic cells. Colcemid-arrested
HeLa S3 cells were used for chromosome purification. Im-
munofluorescence was performed on formaldehyde-fixed
chromosomes using phospho-MAP kinase antibody and
CREST autoimmune serum. The phospho-MAP kinase
localized at the centromeric region of the chromosomes,
resembling the CREST signal (Fig. 6, B and C). Kineto-
chore staining was also seen with an anti-ERK2 polyclonal
Figure 5. Inhibition of phospho-MAP kinase antibody by block-
ing with the phosphopeptide. Vinblastine-treated PtK1 cells were
extracted and fixed, after which indirect immunofluorescence
was performed. The cell in A–C was blocked with the phospho-
peptide CHTGFLpTEpYVATR, whereas the cell shown in D–F
was blocked with the corresponding nonphosphopeptide CHTG-
FLTEYVATR. (A and D) DAPI staining; (B and E) labeling of
phospho-MAP kinase antibody; (C and F) CREST autoimmune
serum labeling. Both peptides were used at 10-fold excess mol/
mol over the antibodies. Bar, 10 mm.The Journal of Cell Biology, Volume 142, 1998 1554
rabbit serum that reacts with both phosphorylated and un-
phosphorylated MAP kinase (data not shown).
CENP-E Is an In Vitro MAP Kinase Substrate
To identify candidate substrates for kinetochore-associ-
ated MAP kinase, we looked for known mitotic proteins
that show the same localization pattern as the phospho-
MAP kinase, have MAP kinase consensus phosphoryla-
tion sites and are phosphorylated in mitosis. Only the ki-
netochore-associated motor protein CENP-E is known to
display a localization pattern similar to phospho-MAP
kinase. CENP-E is first detected at kinetochores at pro-
metaphase (after nuclear envelope breakdown) and stays
at the kinetochores until midanaphase, when its kineto-
chore association diminishes. It then is prominently de-
tected at the spindle midzone in late anaphase, after which
at telophase/cytokinesis it is present in the midbody (Yen
et al., 1991, 1992; Cooke et al., 1997). CENP-E is also re-
ported to be phosphorylated during mitosis (Liao et al.,
1994) and was recently shown to be essential for chromo-
some alignment (Schaar et al., 1997; Wood et al., 1997).
Both human and frog CENP-E contain a COOH-termi-
nal MAP kinase consensus site P-X-S/T-P (serine 2,570 in
human and threonine 2,782 in frog), as well as several XSP
sites that are consensus sites for the cdc2 kinase, but can
be potential phosphorylation sites for MAP kinase as well.
The COOH-terminal portion (amino acids 2,295–2,663;
z45 kD) of the human CENP-E is specifically phosphory-
lated in vivo during mitosis and in vitro by cdc2 kinase
(Liao et al., 1994). This phosphorylation decreases the mi-
crotubule binding ability of the COOH-terminal domain
of CENP-E in vitro (Liao et al., 1994). The corresponding
COOH-terminal CENP-E mutant (CENP-E4A) that has
alanines instead of serines in the XSP consensus (serines
2,567, 2,570, 2,601, and 2,616) is neither phosphorylated in
vivo during mitosis nor in vitro by cdc2 kinase (Yen, T.J.,
unpublished results).
To determine whether MAP kinase can phosphorylate
CENP-E, an in vitro phosphorylation assay was performed
using recombinant activated MAP kinase and recombi-
nant wild-type CENP-E or the serine to alanine mutant
(CENP-E4A) of the COOH-terminal portion of human
CENP-E protein (Fig. 7). The results indicate that the wild-
type COOH-terminal CENP-E protein could be phos-
phorylated by MAP kinase whereas the CENP-E4A mu-
tant was not. None of the reactions without active MAP
kinase showed CENP-E phosphorylation, indicating that
the phosphorylation of the wild-type CENP-E was specifi-
cally due to MAP kinase and not a contaminant in the
CENP-E preparation. All four single-site serine to alanine
CENP-E mutants could be phosphorylated in vitro with
active MAP kinase and no site preference was observed
when phosphopeptide mapping was performed on the
wild-type COOH-terminal CENP-E phosphorylated in
vitro by MAP kinase (data not shown). The same kinetics
of phosphorylation and phosphopeptide maps were ob-
tained by phosphorylating the COOH-terminal domain of
CENP-E in vitro by cdc2 kinase (Liao et al., 1994), indicat-
ing that the two kinases phosphorylate the COOH termi-
nus at the same sites with no preference. Overall, this re-
sult suggests that MAP kinase, as well as cdc2 kinase, can
phosphorylate the COOH-terminus of CENP-E in vitro
on sites known to regulate its microtubule binding ability.
MAP Kinase Associates with CENP-E In Vivo
Because CENP-E is an in vitro MAP kinase substrate and
colocalizes with active MAP kinase at different stages of
mitosis, we tested whether CENP-E and MAP kinase in-
teract in vivo. CENP-E (315 kD) or MAP kinase (42 kD)
were immunoprecipitated from asynchronous or mitotic
HeLa cell lysates, separated on a 4 ®12% SDS gradient
gel, and then the coimmunoprecipitating partner was ana-
lyzed by Western blotting (Fig. 8). CENP-E immunopre-
cipitation showed more CENP-E in mitotic than in inter-
Figure 6. Localization of
phospho-MAP kinase on ki-
netochores of isolated chro-
mosomes. Chromosomes were
obtained from colcemid-
arrested HeLa S3 cells,
which were pelleted onto
coverslips and fixed with 1%
formaldehyde. Immunofluo-
rescence was immediately
performed. (A) DAPI stain-
ing; (B) phospho-MAP ki-
nase antibody labeling; (C)
CREST autoimmune serum
labeling. Arrow, centromeric
region of a chromosome to
which phospho-MAP kinase
antibody and CREST serum
bind, as seen in B and C. Bar,
10 mm.
Figure 7. CENP-E is an in vitro MAP kinase substrate. Autorad-
iograph of a MAP kinase phosphorylation assay using a recombi-
nant wild-type or the corresponding serine to alanine mutant of
the COOH-terminal fragment of human CENP-E protein. Both
bands are CENP-E, the lower being a degradation product.Zecevic et al. Active MAP Kinase in Mitosis 1555
phase cells in agreement with previous findings (Yen et al.,
1992). The phospho-MAP kinase antibody blot revealed that
active MAP kinase coimmunoprecipitated with CENP-E
and that the coimmunoprecipitation from mitotic lysates
was greater than from interphase lysates (Fig. 8 A), even
though more phospho-MAP kinase was present in the in-
terphase lysates (data not shown). Reprobing the mem-
brane with an anti-ERK2 monoclonal antibody showed
unphosphorylated MAP kinase preferentially coimmuno-
precipitated with CENP-E from lysates of asynchronous
cells. Immunoprecipitation of total MAP kinase from cell
lysates revealed coimmunoprecipitation of CENP-E (Fig.
8 B). In this case there was no difference between inter-
phase and mitosis in the amount of coprecipitating CENP-E
protein, presumably because the immunoprecipitating
anti-MAP kinase antibody did not distinguish between
phosphorylated and nonphosphorylated forms of the en-
zyme. These data indicate that CENP-E and MAP kinase
interact in vivo and that this interaction with the phospho-
MAP kinase form is regulated with the cell cycle.
Discussion
Active MAP Kinase Localizes at Kinetochores, Asters, 
and Midbody during Mitosis
In this manuscript we demonstrate that during mitosis a
portion of the phosphorylated and activated MAP kinase
is found at kinetochores, asters, and the midbody. The ki-
netochore localization was first detected and is the stron-
gest at early prometaphase (after nuclear envelope break-
down). It was visible at a reduced level in later prometaphase
stages and metaphase, after which it decreased substan-
tially as anaphase initiated and became undetectable in
midanaphase. This kinetochore localization pattern is con-
sistent with a possible role for MAP kinase in microtubule
capture and chromosome congression in early and mid-
mitotic stages. The temporal pattern in which the kineto-
chore phospho-MAP kinase signal diminishes as anaphase
is initiated is reminiscent of the pattern seen or inferred
with other phosphoepitopes (e.g., 3F3/2 and MPM-2)
(Gorbsky and Ricketts, 1993; Taagepera et al., 1995).
Thus, the dephosphorylation of several proteins is associ-
ated with anaphase onset and is believed to be required
for mitotic progression.
Asters showed localization of active MAP kinase in all
mitotic stages except prophase. Previous work on mouse
oocytes showed MAP kinase at the microtubule organiz-
ing centers (Verhlac et al., 1993). Several centrosomal pro-
teins that have MAP kinase phosphorylation consensus
sites, such as pericentrin (Laird and Shalloway, 1997) and
nuclear mitotic apparatus protein (NUMA) (Sparks et al.,
1995), are also known to be phosphorylated specifically at
mitosis. Interestingly, pericentrin seems to be phosphory-
lated by a kinase that is different from cdc2 kinase (Laird
and Shalloway, 1997). Thus, active MAP kinase might
have an additional role in the assembly and stability of the
centrosomes during mitosis.
At midanaphase, the phospho-MAP kinase signal disap-
pears from kinetochores. It appears at the fibrous area at
the original midzone region in late anaphase and then lo-
calizes at the midbody during telophase and cytokinesis.
Like MAP kinase, inner centromere protein (INCENP)
(Cooke et al., 1987), CENP-E (Yen et al., 1991), and
CENP-F (Rattner et al., 1993; Zhu et al., 1995) translocate
from kinetochores to the midbody at the end of mitosis.
INCENP translocation has been shown to be essential for
proper cytokinesis (Eckley et al., 1997). Therefore, the
movement of active MAP kinase to the midbody raises the
possibility that the enzyme could also play a role in
anaphase B and cytokinesis.
Our localization findings suggest that active MAP ki-
nase plays a role in normal mitotic progression. This seems
to contradict some previous reports suggesting that MAP
kinase activity can disrupt progression through M phase.
For example, sustained MAP kinase activation is neces-
sary for the spindle checkpoint in nocodazole-treated Xe-
nopus egg extracts (Minshull et al., 1994; Takenaka et al.,
1997) and can cause either a G2 or M phase arrest in the
first mitotic cell cycle in Xenopus (Abrieu et al., 1997;
Figure 8. CENP-E associ-
ates with active MAP kinase
during mitosis. Asynchro-
nous or nocodazole-treated
HeLa cells were lysed in a hy-
potonic buffer after which
immunoprecipitation was
performed using a CENP-E
antibody, MAP kinase anti-
body, or beads alone. The im-
munoprecipitated material
was subjected to SDS-PAGE
(4–12% gel), followed by
transfer to nitrocellulose and
Western blotting with ap-
propriate antibodies. (A)
CENP-E immunoprecipita-
tions. Here, single lanes are shown for the bead controls, whereas duplicate lanes are shown for the immunoprecipitations. (B) MAP ki-
nase immunoprecipitations. In both A and B, CENP-E blot, phospho-MAP kinase blot, and ERK2 monoclonal antibody blot (for which
the membrane was previously stripped) is shown. The proteins were visualized by enhanced chemiluminescence.The Journal of Cell Biology, Volume 142, 1998 1556
Walter et al., 1997; Bitangcol et al., 1998). How could one
enzyme function both as a component of normal M phase
progression and as an effector of mitotic arrest? It is possi-
ble that passage from one M phase to another requires cy-
cles of phosphorylation and dephosphorylation of proteins
involved in chromosome movement and cell cycle progres-
sion. On the other hand, sustained phosphorylation of
these proteins might result in M phase arrest. Whether
specific localizations of activated MAP kinase reported
here play a role in M phase arrest remains to be deter-
mined.
Although MAP kinase plays a role in the M phase arrest
in Xenopus egg extracts and early embryos, its ability to
induce M phase arrest in somatic cells is less certain. When
injected into somatic cells, Mos (an in vitro MEK activa-
tor) localized to kinetochores and induced a metaphase-
like arrest (Wang et al., 1994). Although it is clear from
this study that the effect was due to enzymatically acti-
vated Mos, it was not shown that its effect on M phase pro-
gression was due to its kinetochore localization and/or ac-
tivation of MAP kinase. Similarly, injection of MAP
kinase phosphatase CL100 into nocodazole-treated XTC
cells reversed the mitotic arrest (Wang et al., 1997). How-
ever, no determination was made whether MAP kinase
was inactivated in these experiments. Moreover, a recent
report implicating the MAP kinase homologue p38 in M
phase arrest in mammalian cells (Takenaka et al., 1998)
and the fact that CL100 seems to have higher activity for
dephosphorylation of p38 than ERKs (Chu et al., 1996)
raises a question about which of these kinases plays the
predominant role in nocodazole-induced mitotic arrest. It
is possible that in somatic cells the MAP kinases ERK1
and ERK2 are important for normal mitotic progression,
whereas p38 kinase functions in the spindle checkpoint.
MAP Kinase Phosphorylates and Associates with the 
Motor Protein CENP-E
To gain insight into possible functions of MAP kinase in
mitosis, we looked for proteins important in mitosis that
might be candidate MAP kinase substrates, using the fol-
lowing criteria: (a) localization during mitosis similar to
phospho-MAP kinase; (b) presence of MAP kinase con-
sensus phosphorylation sites; and (c) functionally signifi-
cant mitotic phosphorylation. Using these criteria we
identified the kinetochore motor protein CENP-E as a
candidate MAP kinase substrate. The reported localiza-
tion of CENP-E during mitosis coincides with that of
phospho-MAP kinase: it is predominately at the kineto-
chore from early prometaphase until midanaphase and at
the midbody during telophase/cytokinesis (Yen et al.,
1991, 1992; Cooke et al., 1997). The Xenopus homologue
of CENP-E is additionally found at the asters, as is MAP
kinase (Wood et al., 1997). Both human and frog CENP-E
contain MAP kinase consensus phosphorylation sites at
their COOH terminus. Finally, the human CENP-E is re-
ported to be phosphorylated in vivo during mitosis (Liao
et al., 1994).
CENP-E is a kinesin-related motor protein whose kinet-
ochore localization during prometaphase is essential for
bipolar attachment of chromosomes to microtubules and
for proper chromosome congression toward the meta-
phase plate (Shaar et al., 1997; Wood et al., 1997). The hu-
man CENP-E has two microtubule-binding domains: one
at the NH2 terminus whose binding is ATP dependent and
the second one at the COOH terminus whose binding is
ATP independent. The latter domain has four potential
MAP kinase and cdc2 phosphorylation sites, and was
shown to be phosphorylated in vivo during mitosis and in
vitro by cdc2 kinase (Liao et al., 1994).
We find that CENP-E can be a MAP kinase substrate
in vitro. Phosphopeptide maps of the COOH-terminal
CENP-E phosphorylated in vitro by MAP kinase (data
not shown) revealed the same sites as the COOH terminus
of CENP-E phosphorylated in vivo during mitosis and in
vitro by cdc2 (Liao et al., 1994). Since the consensus phos-
phorylation sites for MAP kinase and cdc2 kinase are sim-
ilar and both enzymes can phosphorylate CENP-E in vitro
with similar kinetics and site preference, it is not possible
to be certain which of the kinases is responsible for in vivo
CENP-E phosphorylation or whether both are physiologi-
cally relevant CENP-E kinases. In vitro, CENP-E seems
to be at least as good if not better substrate for MAP ki-
nase than cdc2 (data not shown). We suspect that CENP-E
is a convergence point for regulatory phosphorylation by
several differentially regulated kinases.
We also find that CENP-E and MAP kinase associate in
vivo. Immunoprecipitation of CENP-E coprecipitates MAP
kinase and vice versa. The phospho-MAP kinase is prefer-
entially coimmunoprecipitated from mitotic extracts, and
unphosphorylated MAP kinase is preferentially coimmu-
noprecipitated from interphase extracts. Thus, it is clear
that the association of active MAP kinase and CENP-E is
regulated with the cell cycle. We do not know whether MAP
kinase binds directly to CENP-E or is part of a larger com-
plex.
The requirement for and functions of CENP-E phos-
phorylation are not well understood. The COOH-termi-
nal domain of CENP-E, when phosphorylated in vitro,
showed decreased microtubule binding ability (Liao et al.,
1994). This suggests that in vivo, CENP-E binding to mi-
crotubules via its COOH-terminal domain might depend
on its phosphorylation status. The COOH-terminal do-
main of CENP-E expressed in mitotic cells localized to the
spindle during anaphase but not metaphase, and this is hy-
pothesized to reflect changes in the phosphorylation state
of CENP-E (Liao et al., 1994). At the kinetochore, CENP-E
could potentially bind microtubules via its NH2-terminal
domain throughout mitosis (the binding is ATP dependent
and apparently phosphorylation independent), whereas
the binding to microtubules via its COOH-terminal do-
main would depend on its phosphorylation status. This
implies that in early mitotic stages, when the COOH ter-
minus of CENP-E is phosphorylated, one molecule of
CENP-E will bind via its NH2-terminal domain to only
one microtubule. This could be important in the initial
phases of microtubule capture by kinetochores and in con-
gression. Cycles of phosphorylation and dephosphoryla-
tion of the CENP-E COOH-terminus as congression pro-
ceeds might additionally allow the speed and directionality
of chromosome movement to be titrated, so that chromo-
somes could align at the metaphase plate with minimal en-
tanglements. In anaphase B when the COOH terminus of
CENP-E is unphosphorylated, CENP-E will bind microtu-Zecevic et al. Active MAP Kinase in Mitosis 1557
bules via both its NH2- and COOH-terminal domains. At
the kinetochore, microtubule binding by the COOH ter-
minus of CENP-E may be important for stabilizing kineto-
chore–microtubule interactions during chromatid separa-
tion. In addition, CENP-E is also localized to the spindle
midzone where it may use its two microtubule binding do-
mains to cross-link antiparallel microtubules, stabilizing
the spindle and facilitating pole and chromosome separa-
tion.
During Go transitions, MAP kinase phosphorylates nu-
merous substrates, including receptors, signaling adapters,
transcription factors, and other kinases (L’Allemain, 1994).
It is believed that by phosphorylating multiple substrates
this effector kinase can orchestrate a coordinated but
functionally diverse response to extracellular agonists.
Similarly, we expect that during M phase MAP kinase will
have multiple functionally significant substrates. Since
only a portion of the activated MAP kinase is found at ki-
netochores, asters, and midbody (data not shown), some
of these additional substrates might not be associated with
these structures. It should be noted that MAP kinase was
originally identified as phosphorylating microtubule-asso-
ciated protein-2 (Ray and Sturgill, 1987), and that this
phosphorylation decreases its microtubule stabilizing ac-
tivity (Hoshi et al., 1992). Likewise, active MAP kinase
added to interphase frog egg lysates induces a decrease in
microtubule half-life and forms an M phase microtubule
pattern (Gotoh et al., 1991). Studies are underway to find
additional mitotic MAP kinase substrates and to deter-
mine what changes in mitosis occur when MAP kinase is
ectopically activated or inactivated. 
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